SRPT: Sarepta Therapeutics, Inc. is a Buy
The current rating for SRPT is 53, which is
its historic median rating of 50. This indicates lower risk than normal.
The rating is currently showing a higher than normal reading, suggesting risk levels could be lower than normal.